Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1599)	6/4/2003 12:17:30 AM
From: Miljenko Zuanic	Respond to of 3044

So, hospitals can cut stent in half and there is immediate $1.5K saving. <gr>

To: keokalani'nui who wrote (1599)	6/4/2003 1:43:22 AM
From: Mike	Read Replies (1) \| Respond to of 3044

You are exactly right on the pricing on the Cypher coated stent. The JNJ Cypher stent is priced at $3100-$3400 per stent. What I have seen is hospitals are doing the wrong this is some cases. When a Cypher stent is used the hospital is using heparin only. Now I know this makes no sense and I think is actually dangerous. But I do think that this along with Angiomax "could be" decreasing the total market for 2b/3a's. Remember I don't agree with this but it is happening. Maybe Integrilin is killing Reopro out in the field and the hospital is saving that way. My feeling is MLNM will see a continued slide in business that over the next nine months will hurt the company. Velcade may very well replace it but Integilin sales are huge and profitable. The only problem is this company has never made money. Large R&D expenses and company not measured on profitability. But this has also held the stock back. We will see. Mike